Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy

Arjune Sen, Professor of Global Epilepsy at The University of Oxford, Consultant Neurologist at Oxford University Hospitals NHS Foundation Trust, and coordinating investigator for the CORE-VNS study

“This study provides compelling, real-world evidence supporting the long-term effectiveness and safety of modern VNS Therapy for people living with drug-resistant epilepsy”

Arjune Sen, Professor of Global Epilepsy at The University of Oxford, Consultant Neurologist at Oxford University Hospitals NHS Foundation Trust, and coordinating investigator for the CORE-VNS study

“We observed meaningful clinical benefits as early as three months after implantation, and those benefits endured throughout the study period.”

Arjune Sen, Professor of Global Epilepsy at The University of Oxford, Consultant Neurologist at Oxford University Hospitals NHS Foundation Trust, and coordinating investigator for the CORE-VNS study

“Beyond reducing seizure frequency, the study demonstrated improvements in healthcare utilization and reductions in seizure severity.”

Arjune Sen, Professor of Global Epilepsy at The University of Oxford, Consultant Neurologist at Oxford University Hospitals NHS Foundation Trust, and coordinating investigator for the CORE-VNS study

“The CORE-VNS findings underscore the important role VNS Therapy can play in the long-term management of drug-resistant epilepsy and highlight the importance of timely referral to comprehensive epilepsy centers for evaluation once drug resistance has been established.”

Stephanie Bolton, President, Global Epilepsy at LivaNova

“The findings published in Neuromodulation demonstrate not only a 76% median reduction in seizure frequency at three years but also meaningful benefits across multiple measures important to patients, caregivers, and healthcare systems”

Stephanie Bolton, President, Global Epilepsy at LivaNova

“Most encouragingly, the study showed that benefits from VNS Therapy emerged early and continued to improve over time, reinforcing its important role in the long-term management of Drug-Resistant Epilepsy.”